Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NIH researchers highlight progress, path forward for developing TB vaccines

20.03.2012
In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials.

The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their editorial, co-authored by NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., appears in the journal Tuberculosis to coincide with the publication of Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade.

The new Blueprint on TB vaccines updates the original one, which was published in 2000 as the result of an NIH-sponsored workshop.

Since that time, TB researchers have assembled a significant pipeline of vaccine candidates and assessed them in clinical trials. However, to transform the field and help make licensure of new vaccines a reality, the editorial co-authors stress, scientists must investigate remaining fundamental questions, including the following:

Why does infection with the TB bacterium cause active disease in some people but not others?

Why does the current licensed TB vaccine, Bacille Calmette-Guérin, protect children more effectively than adults?

What immune responses must effective vaccines elicit to successfully protect against TB?

NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical trial data, recent innovations in systems biology, genomics and bioinformatics, animal modeling, and immunologic and molecular tools will play important roles in developing safe and effective TB vaccines. The authors emphasize that close coordination among biomedical researchers, product developers, funders and TB health care programs worldwide will be essential to eventually develop and deliver new vaccines as part of the global fight against TB.

ARTICLE:
C Sizemore and AS Fauci. Transforming biomedical research to develop effective TB vaccines: The next ten years. Tuberculosis 92(S1):S2-S3 (2012).
WHO:
NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., chief of the Tuberculosis, Leprosy and Other Mycobacterial Diseases Section in NIAID's Division of Microbiology and Infectious Diseases, are available to discuss their editorial.
CONTACT:
To schedule interviews, please contact Nalini Padmanabhan, (301) 402-1663, padmanabhannm@niaid.nih.gov.

For more information about the original Blueprint published in 2000, see the NIAID news release announcing its publication. For more information about NIAID's TB research, visit the NIAID Tuberculosis Web portal.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

Nalini Padmanabhan | EurekAlert!
Further information:
http://www.nih.gov

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Explaining how 2-D materials break at the atomic level

18.01.2017 | Materials Sciences

Data analysis optimizes cyber-physical systems in telecommunications and building automation

18.01.2017 | Information Technology

Reducing household waste with less energy

18.01.2017 | Ecology, The Environment and Conservation

VideoLinks
B2B-VideoLinks
More VideoLinks >>>